| 000 | 01307 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517020559.0 | ||
| 264 | 0 | _c20150528 | |
| 008 | 201505s 0 0 eng d | ||
| 022 | _a1756-1833 | ||
| 024 | 7 |
_a10.1136/bmj.h882 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMillard, James | |
| 245 | 0 | 0 |
_aMultidrug resistant tuberculosis. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cFeb 2015 |
||
| 300 |
_ah882 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aGlobal Health |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aPalliative Care |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aPublic Health |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTuberculosis, Multidrug-Resistant _xdiagnosis |
| 700 | 1 | _aUgarte-Gil, Cesar | |
| 700 | 1 | _aMoore, David A J | |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 350 _gp. h882 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.h882 _zAvailable from publisher's website |
| 999 |
_c24659914 _d24659914 |
||